BR112021010715A2 - Pirazolopirimidinas substituídas e purinas substituídas e seu uso como inibidores de protease de processamento ubiquitina-específica 1 (usp1) - Google Patents
Pirazolopirimidinas substituídas e purinas substituídas e seu uso como inibidores de protease de processamento ubiquitina-específica 1 (usp1)Info
- Publication number
- BR112021010715A2 BR112021010715A2 BR112021010715A BR112021010715A BR112021010715A2 BR 112021010715 A2 BR112021010715 A2 BR 112021010715A2 BR 112021010715 A BR112021010715 A BR 112021010715A BR 112021010715 A BR112021010715 A BR 112021010715A BR 112021010715 A2 BR112021010715 A2 BR 112021010715A2
- Authority
- BR
- Brazil
- Prior art keywords
- usp1
- substituted
- ubiquitin
- inhibitors
- specific processing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862783014P | 2018-12-20 | 2018-12-20 | |
| US201962799423P | 2019-01-31 | 2019-01-31 | |
| US201962857986P | 2019-06-06 | 2019-06-06 | |
| US201962868616P | 2019-06-28 | 2019-06-28 | |
| US201962946263P | 2019-12-10 | 2019-12-10 | |
| PCT/US2019/067521 WO2020132269A1 (en) | 2018-12-20 | 2019-12-19 | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021010715A2 true BR112021010715A2 (pt) | 2021-11-16 |
Family
ID=71100912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021010715A BR112021010715A2 (pt) | 2018-12-20 | 2019-12-19 | Pirazolopirimidinas substituídas e purinas substituídas e seu uso como inibidores de protease de processamento ubiquitina-específica 1 (usp1) |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11485736B2 (https=) |
| EP (1) | EP3897652A4 (https=) |
| JP (2) | JP7662519B2 (https=) |
| KR (1) | KR102912147B1 (https=) |
| CN (1) | CN113164485A (https=) |
| AU (1) | AU2019405925B2 (https=) |
| BR (1) | BR112021010715A2 (https=) |
| CA (1) | CA3122108A1 (https=) |
| CL (1) | CL2021001575A1 (https=) |
| CO (1) | CO2021009078A2 (https=) |
| IL (1) | IL284050B2 (https=) |
| MX (1) | MX2021007179A (https=) |
| PH (1) | PH12021551402A1 (https=) |
| SG (1) | SG11202106232TA (https=) |
| TW (2) | TWI895986B (https=) |
| WO (1) | WO2020132269A1 (https=) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10189841B2 (en) | 2015-11-20 | 2019-01-29 | Forma Therapeutics, Inc. | Purinones as ubiquitin-specific protease 1 inhibitors |
| BR112021010715A2 (pt) | 2018-12-20 | 2021-11-16 | Ksq Therapeutics Inc | Pirazolopirimidinas substituídas e purinas substituídas e seu uso como inibidores de protease de processamento ubiquitina-específica 1 (usp1) |
| JP7253640B2 (ja) | 2019-01-31 | 2023-04-06 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| ES3025474T3 (en) * | 2020-01-15 | 2025-06-09 | Ksq Therapeutics Inc | Compositions of substituted pyrazolopyrimidines and uses thereof |
| CA3168009A1 (en) * | 2020-02-14 | 2021-08-19 | KSQ Therapeutics, Inc. | Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors |
| EP4161494A4 (en) * | 2020-06-02 | 2024-07-17 | KSQ Therapeutics, Inc. | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS |
| WO2022053998A1 (en) * | 2020-09-10 | 2022-03-17 | Universidade Do Porto | New pharmaceutical compounds, methods and uses thereof |
| KR20230098186A (ko) * | 2020-10-30 | 2023-07-03 | 케이에스큐 세러퓨틱스 인코포레이티드 | 치환된 피라졸로피리미딘의 고체 상태 형태 및 이의 용도 |
| US20240182481A1 (en) * | 2021-02-15 | 2024-06-06 | Tango Therapeutics, Inc. | Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer |
| AU2022238886A1 (en) * | 2021-03-17 | 2023-09-14 | Medivir Ab | Purine derivatives as anticancer agents |
| MX2023011709A (es) * | 2021-04-07 | 2023-10-12 | Forma Therapeutics Inc | Inhibidor de la proteasa 1 especifica de ubiquitina (usp1). |
| CN117337290B (zh) * | 2021-05-03 | 2026-01-02 | 轩竹生物科技股份有限公司 | 三并环类泛素特异性蛋白酶1抑制剂及其用途 |
| WO2022253188A1 (en) * | 2021-05-31 | 2022-12-08 | Impact Therapeutics (Shanghai) , Inc | Nitrogen-containing fused heteroaromatic bicyclic compounds as usp1 inhibitors and the use thereof |
| GB202114863D0 (en) | 2021-10-18 | 2021-12-01 | Syngenta Crop Protection Ag | Improvements in or relating to organic compounds |
| JP2024540921A (ja) * | 2021-10-19 | 2024-11-06 | 上海瑛派▲薬▼▲業▼有限公司 | Ｕｓｐ１阻害剤としての置換トリアゾロヘテロアリール化合物及びその応用 |
| CN114031556B (zh) * | 2021-11-08 | 2023-03-31 | 温州大学 | 一种绿色的一锅法制备5-氨基-n-芳基-3-芳基吡唑类化合物的合成方法 |
| GEAP202416531A (en) * | 2021-11-12 | 2024-10-28 | Insilico Medicine Ip Ltd | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
| CR20240191A (es) * | 2021-11-12 | 2024-09-13 | Insilico Medicine Ip Ltd | Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos |
| EP4430041A4 (en) * | 2021-11-12 | 2025-09-24 | Insilico Medicine Ip Ltd | SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) AND THEIR USES |
| CN114181237B (zh) * | 2021-12-01 | 2024-02-23 | 上海凌凯医药科技有限公司 | 一种1-异丙基吡唑-5-硼酸频那醇酯的合成方法 |
| IL312982A (en) * | 2021-12-09 | 2024-07-01 | Ksq Therapeutics Inc | Methods for the preparation of converted pyrazolopyrimidines |
| CN118525022A (zh) * | 2022-01-27 | 2024-08-20 | 西藏海思科制药有限公司 | 一种氮杂并环衍生物及其在医药上的应用 |
| US20250163049A1 (en) * | 2022-02-03 | 2025-05-22 | Exelixis, Inc. | Fused bicyclic heterocyclyl compounds as usp1 inhibitors |
| US20250382289A1 (en) * | 2022-02-18 | 2025-12-18 | Xizang Haisco Pharmaceutical Co., Ltd. | Pyrazolopyridine derivative and application thereof in medicine |
| IL315748A (en) * | 2022-04-08 | 2024-11-01 | Ksq Therapeutics Inc | Therapeutic combinations containing ubiquitin-specific processing protease 1 (USP1) inhibitors and chemotherapy agents |
| CN116925098B (zh) * | 2022-04-09 | 2026-02-17 | 深圳湾实验室 | 靶向泛素特异性蛋白酶1(usp1)的小分子抑制剂及其应用 |
| AU2023261809A1 (en) * | 2022-04-29 | 2024-12-05 | Asieris Pharmaceuticals (Shanghai) Co., Ltd. | Pyrimidine compound, method for preparing same, and pharmaceutical use thereof |
| EP4543890A1 (en) * | 2022-06-23 | 2025-04-30 | Forma Therapeutics, Inc. | Usp1 inhibitors and uses thereof |
| WO2024006879A1 (en) * | 2022-06-29 | 2024-01-04 | Zentaur Therapeutics Usa Inc. | Usp1 inhibitors and uses thereof |
| WO2024022266A1 (en) * | 2022-07-25 | 2024-02-01 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heteroaryl compounds as inhibitors of usp1 |
| WO2024022519A1 (zh) * | 2022-07-28 | 2024-02-01 | 先声再明医药有限公司 | 杂环并嘧啶类化合物及其应用 |
| CN119522224A (zh) * | 2022-08-09 | 2025-02-25 | 上海济煜医药科技有限公司 | 含氮杂环化合物作为泛素-特异性蛋白酶1抑制剂的制备方法、应用及其用途 |
| CN117263944B (zh) * | 2022-08-24 | 2025-10-17 | 轩竹生物科技股份有限公司 | 泛素特异性蛋白酶1抑制剂及其用途 |
| CN119790043A (zh) * | 2022-08-26 | 2025-04-08 | 海南先声再明医药股份有限公司 | 三环类化合物及其应用 |
| US20250368667A1 (en) * | 2022-09-02 | 2025-12-04 | Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. | Usp1 inhibitor |
| TW202411231A (zh) * | 2022-09-09 | 2024-03-16 | 大陸商正大天晴藥業集團股份有限公司 | 用作泛素-特異性蛋白酶抑制劑的取代嘌呤酮衍生物 |
| IL319492A (en) * | 2022-09-20 | 2025-05-01 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | A carbonyl-fused heterocyclic derivative that acts as a ubiquitin-specific protease |
| CN117384187B (zh) * | 2022-09-30 | 2026-01-30 | 轩竹生物科技股份有限公司 | 泛素特异性蛋白酶1抑制剂 |
| WO2024078436A1 (zh) * | 2022-10-09 | 2024-04-18 | 海南先声再明医药股份有限公司 | 杂环并嘧啶类化合物、药物组合物及其应用 |
| WO2024086790A1 (en) | 2022-10-21 | 2024-04-25 | Exelixis, Inc. | 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORS |
| WO2024094170A1 (zh) * | 2022-11-04 | 2024-05-10 | 深圳晶泰科技有限公司 | 泛素特异性蛋白酶1的抑制剂及其应用 |
| CN120513237A (zh) | 2023-01-12 | 2025-08-19 | 先正达农作物保护股份公司 | 除草咪唑化合物 |
| CN120603835A (zh) * | 2023-01-20 | 2025-09-05 | 杭州英创医药科技有限公司 | 作为usp1抑制剂的化合物 |
| WO2024222880A1 (zh) * | 2023-04-27 | 2024-10-31 | 西藏海思科制药有限公司 | 一种吡啶并吡唑衍生物的药物组合物及其在医药上的应用 |
| WO2024233605A1 (en) | 2023-05-08 | 2024-11-14 | Tango Therapeutics, Inc. | Compounds and their use against cancer |
| WO2024233665A1 (en) | 2023-05-08 | 2024-11-14 | Tango Therapeutics, Inc. | Compounds and their use against cancer |
| CN116768906B (zh) * | 2023-05-29 | 2024-04-09 | 遵义医科大学珠海校区 | 一种三并环化合物及其制备方法和应用 |
| CN121511238A (zh) * | 2023-07-05 | 2026-02-10 | 江苏亚虹医药科技股份有限公司 | 嘧啶类化合物、其制备方法及其医药用途 |
| CN121219283A (zh) * | 2023-07-05 | 2025-12-26 | 江苏亚虹医药科技股份有限公司 | 联嘧啶化合物的晶型及其制备方法和用途 |
| WO2025010245A1 (en) | 2023-07-06 | 2025-01-09 | Exelixis, Inc. | Fused pyrazole derivatives as usp1 inhibitors |
| WO2025015905A1 (en) * | 2023-07-14 | 2025-01-23 | Laekna Therapeutics Shanghai Co., Ltd. | Pyrimidine compounds and their use as usp1 inhibitors |
| TW202530229A (zh) * | 2023-09-26 | 2025-08-01 | 大陸商上海濟煜醫藥科技有限公司 | 氮雜環胺類化合物作為泛素-特異性蛋白酶１抑制劑的製備方法、應用及其用途 |
| WO2025095751A1 (ko) * | 2023-10-30 | 2025-05-08 | 현대약품 주식회사 | 신규한 화합물, 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| TW202535865A (zh) | 2023-10-31 | 2025-09-16 | 美商必治妥美雅史谷比公司 | 泛素特異性加工蛋白酶1 (usp1) 化合物 |
| WO2025096487A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096488A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025102016A1 (en) | 2023-11-10 | 2025-05-15 | Vrise Therapeutics, Inc. | Novel molecules as inhibitors of dna damage repair pathway |
| WO2025151705A1 (en) | 2024-01-10 | 2025-07-17 | Vrise Therapeutics, Inc. | Novel inhibitors of dna damage repair pathway |
| WO2025180502A1 (zh) * | 2024-03-01 | 2025-09-04 | 上海齐鲁制药研究中心有限公司 | 一种联合用药物组合物及其用途 |
| KR20250138136A (ko) * | 2024-03-12 | 2025-09-19 | 현대약품 주식회사 | 신규한 화합물, 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5010175A (en) | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
| EP0786469B1 (en) | 1990-06-11 | 2006-03-01 | Gilead Sciences, Inc. | Methods of use of nucleic acid ligands |
| AU672790B2 (en) | 1992-07-15 | 1996-10-17 | Novartis Ag | Variants of parathyroid hormone and its fragments |
| AU3204895A (en) | 1995-02-01 | 1996-08-21 | University Of Massachusetts Medical Center | Methods of selecting a random peptide that binds to a target protein |
| EP0934526B1 (en) | 1996-10-08 | 2003-01-08 | U-BISys B.V. | Methods and means for selecting peptides and proteins having specific affinity for a target |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| US9512125B2 (en) * | 2004-11-19 | 2016-12-06 | The Regents Of The University Of California | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents |
| WO2007149484A2 (en) | 2006-06-20 | 2007-12-27 | Dana-Farber Cancer Institute | Inhibitors of usp1 deubiquitinating enzyme complex |
| AU2007325900A1 (en) | 2006-10-20 | 2008-06-05 | Dnar, Inc. | DNA damage repair inhibitors and methods for treating cancer |
| US7964356B2 (en) | 2007-01-16 | 2011-06-21 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| BRPI0817503B8 (pt) * | 2007-10-05 | 2021-05-25 | Sstarbio Pte Ltd | derivados de purina substituídos por pirimidina, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma condição proliferativa |
| CN102014631A (zh) * | 2008-03-03 | 2011-04-13 | 泰格尔医药科技公司 | 酪氨酸激酶抑制剂 |
| JPWO2009157196A1 (ja) * | 2008-06-25 | 2011-12-08 | 武田薬品工業株式会社 | アミド化合物 |
| GB0917934D0 (en) * | 2009-10-13 | 2009-11-25 | Syngenta Ltd | Herbicidal compounds |
| CA2797719C (en) | 2010-04-30 | 2019-11-26 | Dana-Farber Cancer Institute, Inc. | Small molecule inhibitors of usp1 deubiquitinating enzyme activity |
| CA2896731A1 (en) | 2012-12-28 | 2014-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof |
| EP3760719A1 (en) | 2013-11-18 | 2021-01-06 | CRISPR Therapeutics AG | Crispr-cas system materials and methods |
| JP2017510628A (ja) * | 2014-03-13 | 2017-04-13 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | 縮合ピリミジン系ヒドロキサメート誘導体 |
| KR101766194B1 (ko) * | 2015-08-07 | 2017-08-10 | 한국과학기술연구원 | RET 키나아제 저해제인 신규 3-(이속사졸-3-일)-피라졸로[3,4-d]피리미딘-4-아민 화합물 |
| US10189841B2 (en) * | 2015-11-20 | 2019-01-29 | Forma Therapeutics, Inc. | Purinones as ubiquitin-specific protease 1 inhibitors |
| BR112021010715A2 (pt) | 2018-12-20 | 2021-11-16 | Ksq Therapeutics Inc | Pirazolopirimidinas substituídas e purinas substituídas e seu uso como inibidores de protease de processamento ubiquitina-específica 1 (usp1) |
| US20240182481A1 (en) | 2021-02-15 | 2024-06-06 | Tango Therapeutics, Inc. | Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer |
-
2019
- 2019-12-19 BR BR112021010715A patent/BR112021010715A2/pt unknown
- 2019-12-19 TW TW113105437A patent/TWI895986B/zh active
- 2019-12-19 PH PH1/2021/551402A patent/PH12021551402A1/en unknown
- 2019-12-19 JP JP2021531985A patent/JP7662519B2/ja active Active
- 2019-12-19 SG SG11202106232TA patent/SG11202106232TA/en unknown
- 2019-12-19 AU AU2019405925A patent/AU2019405925B2/en active Active
- 2019-12-19 CN CN201980079551.2A patent/CN113164485A/zh active Pending
- 2019-12-19 IL IL284050A patent/IL284050B2/en unknown
- 2019-12-19 US US16/721,079 patent/US11485736B2/en active Active
- 2019-12-19 MX MX2021007179A patent/MX2021007179A/es unknown
- 2019-12-19 EP EP19897934.6A patent/EP3897652A4/en active Pending
- 2019-12-19 KR KR1020217017482A patent/KR102912147B1/ko active Active
- 2019-12-19 WO PCT/US2019/067521 patent/WO2020132269A1/en not_active Ceased
- 2019-12-19 TW TW108146728A patent/TWI834784B/zh active
- 2019-12-19 CA CA3122108A patent/CA3122108A1/en active Pending
-
2021
- 2021-06-16 CL CL2021001575A patent/CL2021001575A1/es unknown
- 2021-07-12 CO CONC2021/0009078A patent/CO2021009078A2/es unknown
-
2022
- 2022-10-11 US US18/045,770 patent/US11787813B2/en active Active
-
2024
- 2024-06-26 JP JP2024102890A patent/JP2024150464A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019405925A1 (en) | 2021-07-29 |
| SG11202106232TA (en) | 2021-07-29 |
| AU2019405925B2 (en) | 2025-07-03 |
| US11787813B2 (en) | 2023-10-17 |
| JP2022511515A (ja) | 2022-01-31 |
| TW202039501A (zh) | 2020-11-01 |
| CN113164485A (zh) | 2021-07-23 |
| US11485736B2 (en) | 2022-11-01 |
| CA3122108A1 (en) | 2020-06-25 |
| TWI895986B (zh) | 2025-09-01 |
| EP3897652A4 (en) | 2022-09-14 |
| KR20210105887A (ko) | 2021-08-27 |
| JP7662519B2 (ja) | 2025-04-15 |
| IL284050A (en) | 2021-08-31 |
| IL284050B1 (en) | 2025-09-01 |
| KR102912147B1 (ko) | 2026-01-13 |
| EP3897652A1 (en) | 2021-10-27 |
| US20230203046A1 (en) | 2023-06-29 |
| CO2021009078A2 (es) | 2021-10-29 |
| MX2021007179A (es) | 2021-09-28 |
| JP2024150464A (ja) | 2024-10-23 |
| IL284050B2 (en) | 2026-01-01 |
| TWI834784B (zh) | 2024-03-11 |
| TW202421630A (zh) | 2024-06-01 |
| PH12021551402A1 (en) | 2023-05-03 |
| CL2021001575A1 (es) | 2022-06-03 |
| US20210115049A1 (en) | 2021-04-22 |
| WO2020132269A1 (en) | 2020-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021010715A2 (pt) | Pirazolopirimidinas substituídas e purinas substituídas e seu uso como inibidores de protease de processamento ubiquitina-específica 1 (usp1) | |
| MX2023007192A (es) | Inhibidores de prmt5. | |
| BR112022008858A2 (pt) | Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer | |
| BR112021023359A2 (pt) | Inibidores de g12c de kras e usos dos mesmos | |
| SA523440916B1 (ar) | Prmt5 مشتقات كربوكساميد ثلاثية الحلقة كمثبطات | |
| BR112022003184A2 (pt) | Inibidores de pirazolo[3,4-b]pirazina shp2 fosfatase | |
| BR112022016382A2 (pt) | Triptaminas específicas para o uso no tratamento de doenças do humor | |
| BR112023015527A2 (pt) | Inibidores de cdk e métodos de uso destes | |
| BR112022009514A2 (pt) | Compostos úteis como inibidores de proteína helios | |
| BR112021026395A2 (pt) | Compostos de 2,3-di-hidroquinazolina como inibidores de nav1.8 | |
| BR112022009571A2 (pt) | Uso de inibidor de fak na preparação de um fármaco para tratar tumores que têm mutação nras | |
| BR112022002532A2 (pt) | Compostos heterocíclicos como inibidores de quinase | |
| MY199409A (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| BR112019007144A2 (pt) | compostos de pirazolo[1,5-a]piridina substituídos como inibidores da ret cinase | |
| BR112022000019A2 (pt) | Composto da fórmula, composição farmacêutica e método de tratamento de câncer | |
| BR112021020285A2 (pt) | Métodos e composições para degradação de proteína alvejada | |
| BR112023009531A2 (pt) | Gcn2 e inibidores de perk quinase e métodos de uso dos mesmos | |
| BR112022000713A2 (pt) | Imidazopirimidinas como inibidores de eed e o uso das mesmas | |
| BR112022010319A2 (pt) | Uso de bi853520 no tratamento de câncer | |
| BR112015016793A2 (pt) | compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim | |
| EA201892075A1 (ru) | Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей | |
| BR112016028819A2 (pt) | composição farmacêutica, métodos para tratar uma doença ou condição em um ser humano e para inibir a atividade de um polipeptídeo de fosfatidilinositol 3-quinase e reações imunológicas excessivas ou destrutivas ou o crescimento ou a proliferação de células cancerosas, kit, composto, sal farmaceuticamente aceitável, isômero ou mistura dos mesmos, e, uso de um composto, sal farmaceuticamente aceitável ou mistura dos mesmos. | |
| BR112021006319A2 (pt) | compostos de indolinona para uso como inibidores de map4k1 | |
| BR112018072740A2 (pt) | realçador de inibidores de homólogo 2 de zeste | |
| BR112021019703A2 (pt) | Compostos heterocíclicos e usos dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |